Wells Fargo & Company Issues Positive Forecast for aTyr Pharma (NASDAQ:ATYR) Stock Price

aTyr Pharma (NASDAQ:ATYR) had its price objective boosted by investment analysts at Wells Fargo & Company from $1.00 to $4.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential downside of 34.36% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Wall Street Zen raised aTyr Pharma to a “hold” rating in a research report on Saturday, October 31st. Weiss Ratings downgraded aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

aTyr Pharma Price Performance

Shares of NASDAQ ATYR opened at $6.09 on Friday. aTyr Pharma has a fifty-two week low of $4.07 and a fifty-two week high of $44.40. The firm has a market capitalization of $14.94 million, a P/E ratio of -0.25 and a beta of 1.04. The company’s 50 day simple moving average is $11.99 and its 200 day simple moving average is $23.70.

aTyr Pharma (NASDAQ:ATYR) last announced its quarterly earnings data on Friday, November 6th. The company reported ($7.43) EPS for the quarter, missing analysts’ consensus estimates of ($4.00) by ($3.43). Sell-side analysts expect that aTyr Pharma will post -17.80 EPS for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

An institutional investor recently raised its position in aTyr Pharma stock. Bank of America Corp DE raised its holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 303,559 shares of the company’s stock after purchasing an additional 176,859 shares during the period. Bank of America Corp DE owned approximately 0.31% of aTyr Pharma worth $237,000 at the end of the most recent quarter. 61.72% of the stock is currently owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.